Fiscal Sponsorship Projects
The Nowak Society has created restricted funds to support specific projects and organization whose aligns with our mission.
Our charitable programming provides other non-profits or grassroots teams the opportunity to build or expand their programs. You can designate a donation to The Nowak Society to support one of our Fiscal Sponsorship Projects. For more information about fiscal sponsorship or to make a larger gift, please contact treasurer@nowaksociety.org.
Our Current Fiscal Sponsorships
Arab Psychedelic Society
Contribute
The Nowak Society’s board of directors has authorized it to create a restricted fund for the Arab Psychedelic Society to receive donations to advance project activities including, but not limited to, psychedelic research, education, training, conferences, retreats, marketing, and community outreach projects.
This fund is determined to advance the organization's activities establishing a founding Board of Directors, developing organizational materials and infrastructure (e.g., website development), other activities pertinent to the foundational groundwork for an emerging association and activities associated with the Project.
Nowak will receive tax deductible gifts, grants, contributions and other revenues from third parties designated for the Fund. It will disburse monies from the Fund, in furtherance of the Project’s mission. Make a contribution to the Fund today.
Right to Try Psilocybin Advocacy Fund
Contribute
Psilocybin advocacy expands in effort to ensure that terminally ill and disabled are able to access psilocybin services under Oregon’s Psilocybin Services Act. The Nowak Society is managing the advocacy fund for Right To Try Psilocybin Advocacy Effort. This effort is to give terminally ill patients access to psilocybin for treatment of anxiety and depression.
About the Right to Try Psilocybin Advocacy Effort
Psilocybin is a drug that has shown promise in treating these conditions, but it is currently illegal because it is classified as a Schedule I drug. The Right To Try laws allow terminally ill patients access to drugs that are still in investigational stages. This fiscally sponsored project of the Nowak Society is working to compel the DEA to issue a waiver allowing access to psilocybin, or to reschedule psilocybin from Schedule I to Schedule II.
Psilocybin Advocacy work under this fund also involves submitting challenges in federal court in Oregon asserting that state and federal disability laws require reasonable accommodation of those whose illness and/or disability require psilocybin service where the individual resides.
On behalf of terminally ill patients suffering anxiety and depression, we are engaged in a multi-dimensional advocacy effort to open access to psilocybin for terminally ill patients Well known patient rights advocate Kathryn Tucker, now the Director of Advocacy for the National Psychedelics Association, represents a Seattle oncology clinic that provides cutting edge integrative medical care, research, and education in oncology, along with the clinic’s palliative care physician/director and a number of his patients with advanced cancer. The physician is seeking approval from DEA for access to psilocybin for therapeutic use with his cancer patients. DEA has denied access. The legal team leading the effort to forge a path to access pursuant to RTT laws will continue to press to compel the DEA to issue a waiver allowing access, and/or to reschedule psilocybin from Schedule I to Schedule II of the Controlled Substances Act. Other strategies to ensure access are also being pursued, including federal legislative action.
Contribute to the Right to Try Psilocybin Advocacy Fund
The Nowak Society, a Colorado 501(c)(3) nonprofit public benefit corporation, is managing the advocacy fund for this effort. All donations are tax-deductible. For questions about the fund or for larger donations via wire transfer or ACH transfer, contact us via email at emerge.rtt.fund@nowaksociety.org.
Additional Links and Resources
Hear updates about Right To Try and the battle for psilocybin access from lead attorney, Kathryn Tucker, in her April 2022 interview with Psychedelics Today, or follow the Kathryn Tucker article archive.
Other media articles of interest include: early Right To Try effort in a 2020 Seattle Times article; a 2022 Scientific American article on patient advocacy in this effort; this final episode in a three part series produced by a cancer advocacy organization on psilocybin therapy, and this Time Magazine profile on Right To Try advocacy efforts.
To learn more about Right To Try Psilocybin Advocacy efforts, please explore these links: